Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

Duke University Medical Center, Durham, North Carolina, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Durham, North Carolina
Treatments:ChemotherapyHospital:Duke University Medical Center
Drugs:Journal:Link
Date:May 2002

Description:

Patients: This Phase II study involved 18 patients with malignant gliomas. Sixteen of the patients had glioblastoma multiforme and 2 patients had anaplastic astrocytoma. All patients had tumors that were resistant to nitrosoureas and had undergone prior radiation therapy.

Treatment: Treatment consisted of two chemotherapy drugs: carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG).

Toxicity: Ten patients experienced grade three or greater thrombocytopenia and eleven patients experienced grade 3 or greater neutropenia. Three patients were removed from the study because they experienced hematopoietic toxicity.

Results: None of the patients demonstrated a partial or complete response.

Support: One of the twenty co-authors of the study had a consulting relationship with Procept which held the license for O(6)-benzylguanine at the time of the study and now has a consulting relationship with Access Oncology which currently hold the license. Three other co-authors are co-inventors of O(6)-benzylguanine.

Correspondence: Jennifer A. Quinn, MD




Back